Students & Trainees

Tim Lee is a Distinguished Scientist who works specifically on early skin cancer detection and epidemiologic research on skin cancer. Tim’s research interests include medical image analysis, artificial intelligence, polarization speckle, computer-aided diagnosis, and risk and prognosis factors of skin cancer.

Research Interests:

• Polarization speckle: in vivo skin cancer screening technique
• Artificial intelligence and computer aided diagnostic algorithms for analyzing skin images
• Risk and prognosis factors for melanoma

Dr. Samuel Aparicio (BM, BCh, PhD, FRCPath, FRSC) is the Nan & Lorraine Robertson Chair in Breast Cancer Research, holds the Canada Research Chair (Tier 1) in Molecular Oncology, and is the recipient of the 2014 Aubrey J Tingle Prize. He is also Head of the Department of Breast and Molecular Oncology at BC Cancer Research, part of the Provincial Health Services Authority, and a Professor in the Department of Pathology and Laboratory Medicine at UBC.  

Dr. Marco Marra has been instrumental in bringing genome science to Canada, working across diverse programs of research that have addressed pressing problems and key opportunities of relevance to Canada and Canadians. He has spent much of his career leading teams to conduct large-scale, high-throughput genomics projects with the aim of comprehensive identification of the gentic changes that drive cancer. He believes that better integration of informatics and biology in genome analysis and a strong interface between the lab and the clinic can change outcomes for cancer patients. 

Dr. Jones’ research program is firmly entrenched in genome science to better understand the complete mutational landscape of cancers. His primary aim is to help uncover the diversity of genetic and genomic events that accrue to give rise to cancers, and which also encourage their evolution and maintain their progression. His laboratory extensively analyzes Next Generation genome and transcriptome data to achieve these goals. Dr.

Dr. Holt has over 200 publications, approximately 118,412 citations, and an H-index of 110. Dr. Holt has been listed in the top 1 per cent of Web of Science cited researchers by Clarivate Analytics in 2018, 2019 and 2020.

Dr. Angela Brooks-Wilson is a distinguished scientist at Canada’s Michael Smith Genome Sciences Centre. Her laboratory group investigates the genetic basis of cancer susceptibility. One of her primary interests is lymphoid cancers, which include Hodgkin lymphoma, non-Hodgkin lymphoma, chronic lymphocytic leukemia and myeloma. Through collaboration with members of the Cancer Control Research Group at BC Cancer including Dr. John Spinelli, Dr. Brooks-Wilson studies the interaction between genetic susceptibility and environmental triggers in causing lymphoid cancers.

Dr. Gregg Morin received his PhD in Biochemistry from the University of Colorado, Boulder in 1988. Following a postdoctoral fellowship in the Department of Molecular Biophysics and Biochemistry at Yale University and an assistant professorship at the University of California, Davis, Dr. Morin was the Director of the Department of Molecular Biology and Biochemistry at Geron Corporation. In 2004, he joined Canada’s Michael Smith Genome Sciences Centre where he is currently the Head of Proteomics.

Dr. Hirst is a Distinguished Scientist and Head of Epigenomics at Canada’s Michael Smith Genome Sciences Centre at BC Cancer, Professor in the Department of Microbiology and Immunology and Associate Director of the Michael Smith Laboratory at the University of British Columbia (UBC).

Dr. Gorski completed a PhD in Biology and Biomedical Sciences at Washington University School of Medicine, St. Louis, MO in 1999. She then conducted postdoctoral studies at the BC Cancer where she utilized genomics approaches to study cell death and cell survival pathways. Dr. Gorski is currently a Distinguished Scientist at Canada’s Michael Smith Genome Sciences Centre at BC Cancer and a Professor in the Department of Molecular Biology and Biochemistry at Simon Fraser University.

Dr. Sadar has served in leadership roles internationally and was the first Canadian to serve as Chair of the USA Army’s Department of Defence’s Programmatic Panel for Prostate Cancer Research. She was President of the Society of Basic Urologic Research (USA) and a board member of education, research, and scientific advisory committees and boards for American and Canadian non-profit societies. Of note, Dr. Sadar was appointed to the Board of Trustees for Canada’s National Museum of Science and Technology by the Minister of Heritage.

Dr. Isabella Tai is interested in understanding the mechanisms of chemotherapy resistance, metastasis and tumour progression in gastrointestinal cancers. Her group uses genomic and proteomic approaches to identify genetic markers that could be suitable for colorectal cancer screening, and to identify unique signatures that correspond to drug resistance in colorectal cancers.

Dr. Stuart Peacock holds the Leslie Diamond Chair in Cancer Survivorship in the Faculty of Health Sciences at Simon Fraser University. He is Co-Director of the Canadian Centre for Applied Research in Cancer Control (ARCC) and Head of Cancer Control Research at BC Cancer. He is also a member of the Board of Directors of the Canadian Agency for Drugs and Technologies in Health, and past President of the International Society on Priorities in Health Care. He has held university positions in Canada, Australia and the UK.

Dr.

Dr. Ryan Morin has been studying the genetic nature of lymphoid cancers using genomic methods for more than a decade. During his doctoral training at the University of British Columbia and BC Cancer, he pioneered the use of transcriptome and whole genome sequencing to identify driver mutations in non-Hodgkin lymphomas. Over the course of his training, he published a series of papers describing some of the most common genetic features of diffuse large B-cell (DLBCL) and follicular lymphomas including EZH2, KMT2D, CREBBP and MEF2B.

Our lab is interested in both the effects of various diets on cancer (CA) incidence and in determining who is at risk of developing CA so we can prevent it by adopting life style changes. In regard to the first goal, since tumour cells are more dependent on blood glucose than normal cells for their growth, we have been testing low carbohydrate (CHO) diets on mice and found they reduce the incidence, growth rate and metastasis of primary tumours.

Dr. Florian Kuchenbauer received his M.D. education at the Ludwig-Maximilians-University in Munich, Germany in 2001 and completed an M.D. thesis at the Max-Planck-Institute for Psychiatry in 2002. He then started residency training at the Department of Hematology/Oncology, Klinikum Grosshadern, Munich, Germany (2001-2004) before obtaining a PhD degree at the Terry Fox Laboratory, BC Cancer and Department of Experimental Medicine, University of British Columbia under the supervision of Dr. Keith Humphries (2005-2009).

Peter Lansdorp was born and raised in the Netherlands. He was trained as a medical doctor at the Erasmus University in Rotterdam and obtained a PhD from the University of Amsterdam. In 1985 he moved to the Terry Fox Laboratory in Vancouver, where he worked on the purification and biology of human and murine blood forming stem cells. This work led him to studies of telomere biology for which he developed quantitative fluorescence in situ hybridization (Q-FISH) techniques. These techniques have become standard in the telomere field.

Dr. Andrew Weng pursued his undergraduate studies in Biological Sciences at Stanford University before earning both MD and PhD degrees from the University of Chicago/Pritzker School of Medicine. His professional journey continued with residency training in Anatomic Pathology and a fellowship in hematopathology, followed by postdoctoral research at Brigham & Women’s Hospital in Boston.

Dr. Rahmim is Professor of Radiology, Physics and Biomedical Engineering at the University of British Columbia (UBC), as well as Distinguished Scientist and Provincial Medical Imaging Physicist at BC Cancer. He received his MSc in condensed matter physics and PhD in medical imaging physics at UBC.

Dr. Rachel Murphy is a Senior Scientist at the BC Cancer and an Associate Professor at the School of Population and Public Health, University of British Columbia. She received her PhD in Nutrition and Metabolism from the University of Alberta and completed a post doctorate in the Laboratory of Epidemiology, and Population Sciences at the National Institute on Aging in the United States. Her research program aims to advance the understanding of relationships between diet, nutrition and chronic disease, particularly cancer.

The overarching goal of our laboratory is to understand the control of stem cells in development and diseases. Our research group is focused on uncovering novel mechanisms of post-transcriptional and translational regulation during normal and malignant hematopoiesis. We aim to develop innovative therapeutic approaches targeting these regulatory pathways in cancer.

Dr. Laura Evgin’s research is focused on chimeric antigen receptor (CAR) modified T cells and their use in conjunction with oncolytic viruses (OVs). OVs can help to overcome the myriad of immunosuppressive mechanisms employed by solid tumours to evade the immune system and which limit CAR T efficacy. She employs CRISPR to generate CAR T cells that can withstand the onslaught of inflammatory factors they are faced with when combined with oncolytic virus therapy.

Dr Leandro Venturutti began his scientific career at the Faculty of Pharmacy and Biochemistry (University of Buenos Aires, Argentina), where he studied the structure and function of a protein lost in the hereditary neurodegenerative disease Friedreich Ataxia. Pursuing his profound interest in biomedical sciences and mechanisms of disease, he moved on to the cancer research field for his PhD studies.

Dr. Adi Steif’s research is focused on developing and applying computational methods for high-throughput genomics, with a particular interest in characterizing disease mechanisms and evolution in the context of cancer. New measurement technologies are enabling large-scale genetic, transcriptomic and epigenetic profiling of tissues at the single cell level. Working alongside experimental collaborators, Dr. Steif uses statistical machine learning approaches to derive biological insights from these high-dimensional datasets in the presence of noise and measurement bias.

Professor ǀ OBMS ǀ Faculty of Dentistry 

Director, BC Oral Cancer Prevention Program: http://www.bccancer.bc.ca/health-professionals/clinical-resources/oral